Abstract:Key points: Limb-girdle muscular dystrophy R1 (LGMD R1) is caused by mutations in the CAPN3 gene and is characterized by progressive muscle loss, impaired mitochondrial function and reductions in the slow oxidative gene expression programme. Myostatin is a negative regulator of muscle growth, and its inhibition improves the phenotype in several muscle wasting disorders. The effect of genetic and pharmacological inhibition of myostatin signalling on the disease phenotype in a mouse model of LGMD R1 (CAPN3 knockout mouse-C3KO) was studied. Inhibition of myostatin signalling in C3KO muscles resulted in significant muscle hypertrophy; however, there were no improvements in muscle strength and exacerbation of exercise intolerance concomitant with further reduction of muscle oxidative capacity was observed. Inhibition of myostatin signalling is unlikely to be a valid therapeutic strategy for LGMD R1. Abstract: Limb-girdle muscular dystrophy R1 (LGMD R1) is caused by mutations in the CAPN3 gene and is characterized by progressive muscle loss, impaired mitochondrial function and reductions in the slow oxidative gene expression programme. There are currently no therapies available to patients. We sought to determine if induction of muscle growth, through myostatin inhibition, represents a viable therapeutic strategy for this disease. Myostatin is a negative regulator of muscle growth, and its inhibition improves the phenotype in several muscle wasting disorders. However, the effect of myostatin depends on the genetic and pathophysiological context and may not be efficacious in all contexts. We found that genetic inhibition of myostatin through overexpression of follistatin (an endogenous inhibitor of myostatin) in our LGMD R1 model (C3KO) resulted in 1.5- to 2-fold increase of muscle mass for the majority of limb muscles. However, muscle strength was not improved and exercise intolerance was exacerbated. Pharmacological inhibition of myostatin, using an anti-myostatin antibody, resulted in statistically significant increases in muscle mass; however, functional testing did not reveal changes in muscle strength nor endurance in treated C3KO mice. Histochemical and biochemical evaluation of follistatin overexpressing mice revealed a reduction in the percentage of oxidative fibres and decreased activation of AMP-activated protein kinase signalling in transgenics compared to C3KO muscles. Our data suggest that muscle hypertrophy, induced by myostatin inhibition, leads to loss of oxidative capacity, which further compromises metabolically impaired C3KO muscles and thus is unlikely to be a valid strategy for treatment of LGMD R1.

Functional replacement of myostatin with GDF-11 in the germline of mice

Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1α-Fndc5 pathway in muscle.

Functional verification of a porcine myostatin propeptide mutant

The Growth Differentiation Factor 11 (GDF11) and Myostatin (MSTN) in Tissue Specific Aging

Effective MSTN Gene Knockout by AdV-Delivered CRISPR/Cas9 in Postnatal Chick Leg Muscle.

PSIII-4 Evaluating Potential Interactive Effects of the IGF2 Intron3 g.3072a Substitution and Myostatin Loss-of-Function on Growth in Mice

Administration of a Mutated Myostatin Propeptide to Neonatal Mice Significantly Enhances Skeletal Muscle Growth

Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A

HMEJ-mediated site-specific integration of a myostatin inhibitor increases skeletal muscle mass in porcine

Establishment and Phenotypic Analysis of an Mstn Knockout Rat.

The critical role of myostatin in differentiation of sheep myoblasts.

Mss51 Deletion Enhances Muscle Metabolism and Glucose Homeostasis in Mice

Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy

Therapeutic targeting of GDF11 in muscle atrophy: Insights and strategies

Inhibition of myostatin in adult mice increases skeletal muscle mass and strength

The role of GDF11 in aging and skeletal muscle, cardiac and bone homeostasis

Myostatin inhibition promotes fast fibre hypertrophy but causes loss of AMP-activated protein kinase signalling and poor exercise tolerance in a model of limb-girdle muscular dystrophy R1/2A

Local versus systemic control of bone and skeletal muscle mass by components of the transforming growth factor-β signaling pathway

Research Progress on Myostatin

Myostatin Gene Mutated Mice Induced with Tale Nucleases.

Myostatin Knockout Affects Mitochondrial Function by Inhibiting the AMPK/SIRT1/PGC1α Pathway in Skeletal Muscle